Business
Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55
Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55 ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Nov. 14, 2017\n\n\n\nTORONTO and HOUSTON, TX, Nov. 14, 2017 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX \"MDNA\"), a clinical stage immuno-oncology company, announced that that Dr. Martin Bexon, MD, Head of Clinical Development at Medicenna, will present today results from earlier clinical trials at the Cancer Prevention and Research Institute of Texas' (\"CPRIT\") Fifth Innovations in Cancer Prevention and Research Conference held from November 13-14, 2017 in Austin, TX.   \n\nThe poster presentation by Dr. Bexon provides an overview of the safety and efficacy results from previous Phase 1 and 2 clinical trials of the targeted immunotherapy, MDNA55, in 66 patients with recurrent glioblastoma (rGBM), the most common and deadly form of brain cancer. \n\nIn the MDNA55 Phase 1 multicenter study, an overall response rate (ORR) of 56% was achieved, with a complete response rate of 20%. Rapid tumor necrosis was observed in ~50% of MDNA55 patients with a partial or a complete response indicating MDNA55-depedent tumor cytotoxicity. Comparable ORR with other therapeutics in rGBM patients in various clinical trials has ranged from 4 to 6% (Levin VA, et al., Neuro-Oncology 17:vi1–vi26, 2015).\n\nAnalysis of efficacy data, across the MDNA55 Phase 1 and 2 studies, showed a median survival of 210 days post infusion in all rGBM patients irrespective of the number of relapses. Among patients with a partial or complete response median survival was 12.5 months with overall survival at 6 and 12 months (OS-6 and OS-12) of 71% and 57%, respectively, following a single administration of MDNA55.\n\nIn addition to promising efficacy data the clinical trial demonstrated the excellent safety profile of MDNA55 including:\n\n\nNo systemic toxicity following doses of 6 – 900 μg.\nNo clinically significant laboratory abnormalities.\nNo de...